About Ataraxis AI

Ataraxis is a clinical AI research lab working at the intersection of multi-modal AI and precision medicine. Our goal is to make disease predictable. To accomplish this, we develop new AI methods that predict patient outcomes and treatment response, and build clinical tools to assist physicians in selecting the most optimal treatments for their patients.

Our AI research lab discovers and develops methods to recognize patterns and predict outcomes across complex, multi-modal clinical data. This spans our causality (Ataraxis™ Tau), foundation model (Falcon and Kestrel for digital pathology), and survival analysis research.

Our first clinical products, such as Ataraxis™ Breast for breast cancer, already help patients get the most appropriate treatment across the best academic institutions and community clinics worldwide.

At Ataraxis, you will have a unique opportunity to shape not only the future of our company, but also the future of healthcare. You will join an exceptional team at the forefront of clinical AI research and deployment. Our advisors include AI pioneers such as our founding advisor, Yann LeCun, and distinguished oncologists from top cancer research institutions, all united by the mission to redefine precision medicine.

Ataraxis has raised over $24 million in funding, including a $20 million Series A led by top venture capital funds such as Thiel Capital/Founders Fund (OpenAI, SpaceX, Palantir), Obvious Ventures (AMI Labs, Inceptive, Radical Numerics, Recursion), and AIX Ventures (Hugging Face, Perplexity).

We are an company with a flat organizational structure, where every team member is empowered to actively contribute. Leadership roles are earned by those who demonstrate initiative and consistently deliver exceptional results. Strong work ethic and the ability to prioritize ruthlessly are essential.

Responsibilities

Aggressively drive sales growth and market penetration of Ataraxis oncology products through direct sales to individual oncologists within your designated territory.
Prospecting new business and maintaining relationships.

Qualifications

Minimum 2 years of demonstrated high-performance sales experience in oncology, especially in breast cancer.
Proven track record of consistently exceeding sales quotas and demonstrated achievement through awards or recognition (e.g., President's Club, Rookie of the Year).
Passionate about AI and innovation in healthcare, driven to learn and effectively communicate AI-based diagnostic solutions.
Autonomous, capable of excelling independently in a hyper-growth start-up environment.
Ability to thrive in a highly competitive environment; demonstrates resilience, urgency, and focus on closing deals.

About the company

Ataraxis.ai creates precision medicine tools for cancer care using artificial intelligence. Its first product, Ataraxis Breast, is an AI-native prognostic test for breast cancer designed to predict patient outcomes more accurately and help doctors personalize treatment plans. Results are delivered quickly, within one business day, through a physician portal or to clinicians. The company differentiates itself by offering an AI-driven prognostic test that aims to set a new standard in molecular diagnostics rather than relying on traditional methods alone, with a focus on rapid, actionable insights for oncology. The goal is to improve how cancer treatment decisions are made by providing fast, data-driven prognostic information to physicians and healthcare providers.

Company Size

11-50

Company Stage

Series A

Total Funding

$44.8M

Headquarters

New York City, New York

Founded

2023

Get referred to Ataraxis.ai

See people who can refer or advise you

Simplify's Take

What believers are saying

Ataraxis launched ARC in 2026, creating prospective evidence for broader commercialization.
California licensure and CAP accreditation expanded access for clinicians and patients statewide.
The $20.4 million Series A funded breast test launch and expansion into solid tumors.

What critics are saying

Exact reimbursement remains undisclosed, so 2026 revenue depends on clinician adoption and self-pay demand.
Tempus and Foundation Medicine already own oncology workflows, pressuring Ataraxis's sales cycle.
If Breast test performance disappoints in prospective ARC studies, Ataraxis loses its entire platform thesis.

What makes Ataraxis.ai unique

Ataraxis Breast uses causal multimodal AI, not generic pathology scoring, across CTX and NEO.
The platform validated on TAILORx, UNIRAD, and 11,135 patients across 17 cohorts.
CAP-accredited, California-licensed laboratory delivery makes Ataraxis a regulated, clinic-ready diagnostics vendor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

43%

1 year growth

43%

2 year growth

91%

Epium Ltd

Sep 18th, 2026

Ataraxis AI unveils models for cancer treatment prediction.

Ataraxis AI unveils models for cancer treatment prediction. Ataraxis AI announced a new generation of models built to predict treatment response and patient outcomes, with an initial focus on breast cancer and broader testing across solid tumors. The company said the models can generalize zero-shot from breast cancer to multiple solid tumors, positioning the work as a step toward more personalized oncology treatment planning. The company is releasing three research papers, including a study on causal AI methods applied to predicting chemotherapy benefit and patient outcomes in breast cancer. The study covers 11,135 patients across 17 cohorts, followed by zero-shot generalization in 6,692 patients across 16 cancer types. Two additional papers report clinical validation in TAILORx Phase III trial and UNIRAD Phase III trial. Ataraxis said TAILORx Phase III trial results confirmed statistically significant chemotherapy benefit predictions, while UNIRAD Phase III trial findings showed predictions of outcomes and treatment benefit in high-risk breast cancer, including benefit from everolimus. The models are based on causal AI methods that learn to simulate patient outcomes under counterfactual scenarios using longitudinal data. Ataraxis has incorporated those methods into Ataraxis Tau, an AI world model intended to support future tools for building personalized treatment plans across oncology. Originally reported by oncodaily.com Read the source

Newzchain

Aug 7th, 2026

Ataraxis AI raises $20M to predict cancer outcomes and reduce unnecessary chemotherapy

Ataraxis AI has raised $20.4 million in a Series A round led by AIX Ventures to commercialise its cancer treatment prediction technology. Thiel Bio, Founders Fund, Floating Point, Bertelsmann, Giant Ventures and Obvious Ventures also participated. The company previously raised $4 million in seed funding. The startup analyses high-resolution images of cancer cells using AI trained on hundreds of millions of images from thousands of patients. According to Ataraxis, its technology is 30% more accurate than current standards for breast cancer care. The funding will support the commercial launch of its first breast cancer test and expansion into other cancer types. Co-founded by Jan Witowski and NYU professor Krzysztof Geras, Ataraxis aims to help predict long-term cancer outcomes and potentially reduce unnecessary chemotherapy treatments.

Business Wire

Mar 30th, 2026

Ataraxis AI launches first predictive test estimating individualised chemotherapy benefit in breast cancer

Ataraxis AI has launched Ataraxis Breast CTX, an AI-powered test that estimates individualised chemotherapy benefit in breast cancer patients. The platform combines digitised pathology slides with clinical data to predict patient-level outcomes with and without adjuvant chemotherapy. The test was developed using multimodal data from over 10,000 breast cancer patients worldwide and validated across observational studies and randomised controlled trials. It has been adopted by top NCI-designated cancer centres and community clinics across the United States. Ataraxis Breast CTX uses the company's Tau causal inference layer to account for treatment selection bias. The platform aims to identify high-risk patients unlikely to benefit from chemotherapy, helping clinicians make more informed treatment decisions and potentially reduce overtreatment. The test is offered through a CLIA-certified laboratory.

Femtech Insider

Mar 14th, 2025

Ataraxis AI Raises $20.4M for Cancer Diagnostics

Ataraxis AI has raised $20 million in Series A funding to advance its AI precision medicine platform, focusing on Ataraxis Breast for breast cancer diagnostics. Led by AIX Ventures, the round included investors like Thiel Bio and Founders Fund. The Kestrel model, central to their platform, is 30% more accurate than current standards. The funding will aid in expanding treatment capabilities and developing new AI models, with plans to launch Ataraxis Breast in the U.S. later this year.

AlleyWatch

Mar 10th, 2025

Ataraxis AI raises $20.4M Series A

Ataraxis, an AI precision medicine company focused on cancer diagnostics, has raised $20 million in Series A funding led by AIX Ventures. Founded by Jan Witowski and Krzysztof Geras in 2022, Ataraxis has now raised a total of $24 million in reported equity funding.

Ataraxis.ai

Oncology Specialist

About the job